Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13265451 | 0.84 | NAAA (0.48) | HRH3DRD3PAOXRAB9ASLC29A1 | |
| SCHEMBL11025698 | 0.83 | HRH3 (0.47) | HRH3DRD3PAOXRAB9ASLC29A1 | |
| SCHEMBL14641556 | 0.82 | HRH3 (0.49) | HRH3DRD3PAOXRAB9ASLC29A1 | |
| SCHEMBL561431 | 0.81 | SMN1; SMN2 (0.52) | HRH3ALDH1A1USP2MEN1LMNA | |
| SCHEMBL561818 | 0.81 | HRH2 (0.44) | HRH3RAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL16845085 | 0.80 | HRH3 (0.50) | HRH3DRD3PAOXRAB9ASLC29A1 | |
| SCHEMBL1301323 | 0.79 | HRH3 (0.49) | HRH3DRD3PAOXRAB9ASLC29A1 | |
| SCHEMBL24219772 | 0.77 | HRH3 (0.48) | HRH3DRD3PAOXRAB9ASLC29A1 | |
| SCHEMBL13520211 | 0.77 | HRH2 (0.40) | DRD3SLC29A1ALDH1A1MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL1950623 | 0.77 | HRH3 (0.48) | HRH3DRD3PAOXRAB9ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140322740-A1 | PSA PEPTIDASE ACTIVITY (PPA) AS A PROSTATE CANCER BIOMARKER | NORTHWESTERN UNIVERSITY, AN ILLINOIS NOT FOR PROFIT CORPORATION (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140134658-A1 | PSA ENZYMATIC ACTIVITY: A NEW BIOMARKER FOR ASSESSING PROSTATE CANCER AGGRESSIVENESS | NOTRHWESTERN UNIVERSITY, AN ILLINOIS NOT FOR PROFIT CORPORATION (US) | 2014-05-15 | — | — | US | disclosed |
| US-20120034638-A1 | Electrochemical assay for the detection of enzymatically active PSA | NORTHWESTERN UNIVERSITY, AN ILLINOIS NOT FOR PROFIT CORPORATION | 2012-02-09 | — | — | US | disclosed |
| US-6844318-B2 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | BRISTOL MYERS SQUIBB PHARMA COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| EP-1263473-A2 | PEPTIDASE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR THERAPEUTIC USE | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020103133-A1 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-01 | — | — | US | disclosed |
| WO-2001068145-A2 | PEPTIDASE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR THERAPEUTIC USE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103133-A1 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | DNPEP, TMPRSS15, ENPEP | HRH3 2329/4885DRD3 4295/4885PAOX 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.